Chandra Patel, PhD

Vice President
GentiBio, Inc
Cambridge, Massachusetts, United States

Disclosure information not submitted.

Presentation(s):

• SAT-568 - Early-Phase Clinical Evaluation Of GNTI-122, An Engineered Regulatory T Cell Therapy, In Recent-Onset Type 1 Diabetes

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT